$71.00
0.40.57%
At Close: -
$71.00
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Conmed (NYSE:CNMD) Stock, Analyst Ratings, Price Targets, Forecasts
Conmed Corp has a consensus price target of $104.11 based on the ratings of 9 analysts. The high is $141 issued by Keybanc on July 27, 2023. The low is $75 issued by JP Morgan on April 25, 2024. The 3 most-recent analyst ratings were released by Needham, Needham, and JP Morgan on July 25, 2024, May 6, 2024, and April 25, 2024, respectively. With an average price target of $96 between Needham, Needham, and JP Morgan, there's an implied 35.21% upside for Conmed Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
JP Morgan
Wells Fargo
Piper Sandler
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Conmed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | Buy Now | 49.3% | Needham | Mike Matson | $107 → $106 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 50.7% | Needham | Mike Matson | → $107 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 5.63% | JP Morgan | Robbie Marcus | $115 → $75 | Maintains | Overweight | Get Alert |
| 04/25/2024 | Buy Now | 8.45% | Wells Fargo | Vik Chopra | $98 → $77 | Maintains | Equal-Weight | Get Alert |
| 04/25/2024 | Buy Now | 33.8% | Piper Sandler | Matt O'Brien | $100 → $95 | Maintains | Overweight | Get Alert |
| 04/25/2024 | Buy Now | 50.7% | Needham | Mike Matson | $129 → $107 | Maintains | Buy | Get Alert |
| 02/01/2024 | Buy Now | 40.85% | Piper Sandler | Matt O'Brien | $130 → $100 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 61.97% | JP Morgan | Robbie Marcus | $135 → $115 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 38.03% | Wells Fargo | Durgesh Chopra | $107 → $98 | Maintains | Equal-Weight | Get Alert |
| 02/01/2024 | Buy Now | 81.69% | Needham | Mike Matson | $119 → $129 | Maintains | Buy | Get Alert |
| 10/27/2023 | Buy Now | 83.1% | Piper Sandler | Matt O'Brien | $145 → $130 | Maintains | Overweight | Get Alert |
| 10/26/2023 | Buy Now | 69.01% | Stifel | Rick Wise | $136 → $120 | Maintains | Buy | Get Alert |
| 10/26/2023 | Buy Now | 50.7% | Wells Fargo | Durgesh Chopra | $123 → $107 | Maintains | Equal-Weight | Get Alert |
| 10/26/2023 | Buy Now | 67.61% | Needham | Mike Matson | $140 → $119 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | 104.23% | JP Morgan | Robbie Marcus | $125 → $145 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | 97.18% | Needham | Mike Matson | $139 → $140 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | 98.59% | Keybanc | Matthew Mishan | $131 → $141 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | 95.77% | Needham | Mike Matson | → $139 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 95.77% | Needham | Mike Matson | $135 → $139 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | 97.18% | CL King | Kristen Stewart | → $140 | Initiates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 83.1% | Stifel | Rick Wise | $118 → $130 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 80.28% | Piper Sandler | Matt O'Brien | $118 → $128 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | 67.61% | Wells Fargo | Durgesh Chopra | $96 → $119 | Maintains | Equal-Weight | Get Alert |
| 04/27/2023 | Buy Now | 90.14% | Needham | Mike Matson | $122 → $135 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 84.51% | Keybanc | Matthew Mishan | $124 → $131 | Maintains | Overweight | Get Alert |
| 03/27/2023 | Buy Now | 74.65% | Keybanc | Matthew Mishan | → $124 | Upgrade | Sector Weight → Overweight | Get Alert |
| 02/03/2023 | Buy Now | 66.2% | Piper Sandler | Matt O'Brien | $108 → $118 | Maintains | Overweight | Get Alert |
| 02/03/2023 | Buy Now | 71.83% | Needham | Mike Matson | $106 → $122 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 49.3% | Needham | Mike Matson | $90 → $106 | Maintains | Buy | Get Alert |
| 10/14/2022 | Buy Now | 26.76% | Needham | Mike Matson | $123 → $90 | Maintains | Buy | Get Alert |
| 10/12/2022 | Buy Now | 19.72% | Jefferies | Matthew Taylor | → $85 | Initiates | → Hold | Get Alert |
| 08/02/2022 | Buy Now | 73.24% | Needham | Mike Matson | $127 → $123 | Maintains | Buy | Get Alert |
| 07/28/2022 | Buy Now | 66.2% | Piper Sandler | Matt O'Brien | $160 → $118 | Maintains | Overweight | Get Alert |
| 07/28/2022 | Buy Now | 78.87% | Needham | Mike Matson | $155 → $127 | Maintains | Buy | Get Alert |
| 06/23/2022 | Buy Now | 54.93% | Stifel | Rick Wise | $160 → $110 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 118.31% | Needham | Mike Matson | $150 → $155 | Maintains | Buy | Get Alert |
| 01/21/2022 | Buy Now | 111.27% | Needham | Mike Matson | $158 → $150 | Maintains | Buy | Get Alert |
| 10/28/2021 | Buy Now | 122.54% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
| 10/06/2021 | Buy Now | 111.27% | Needham | Mike Matson | — | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Conmed (CNMD) stock?
The latest price target for Conmed (NYSE:CNMD) was reported by Needham on July 25, 2024. The analyst firm set a price target for $106.00 expecting CNMD to rise to within 12 months (a possible 49.30% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Conmed (CNMD)?
The latest analyst rating for Conmed (NYSE:CNMD) was provided by Needham, and Conmed maintained their buy rating.
When was the last upgrade for Conmed (CNMD)?
The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.
When was the last downgrade for Conmed (CNMD)?
There is no last downgrade for Conmed.
When is the next analyst rating going to be posted or updated for Conmed (CNMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
Is the Analyst Rating Conmed (CNMD) correct?
While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $107.00 to $106.00. The current price Conmed (CNMD) is trading at is $71.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.